Literature DB >> 15654657

Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan.

Kiyokazu Akioka1, Sirou Takahara, Seiji Ichikawa, Norio Yoshimura, Takahiro Akiyama, Shinichi Ohshima.   

Abstract

A multicenter retrospective study was conducted in 936 living donor kidney transplant recipients treated with cyclosporine (CsA) or tacrolimus (FK) from April 1982. The influences of acute rejection, hyperlipidemia, and hypertension were estimated by Kaplan-Meier's analysis and Wilcoxon's analysis. Of 916 recipients, 532 (58.1%) had acute rejections. The 5- and 10-year graft survival rates in the recipients with acute rejection were 75.2% and 55.2%, respectively. The corresponding rates of the recipients without acute rejection were 80.2% and 70.6%, respectively. The graft survival rate was worse in recipients with late-phase rejection and multiple rejection episodes (p < 0.00006). Of 451 recipients, 176 (39.0%) had hypercholesterolemia 3 years after kidney transplantation. The 5- and 10-year graft survival rates in the recipients with hypercholesterolemia were 88.7% and 68.7%, respectively. Those of the recipients without hypercholesterolemia were 95.2% and 83.9%, respectively. The graft survival rate in the recipients with hypercholesterolemia was lower than that in the recipients without hypercholesterolemia (p = 0.003). Of 323 recipients, 123 (38.1%) had hypertriglyceridemia 3 years after kidney transplantation. The 5- and 10-year graft survival rates in the recipients with hypertriglyceridemia were 93.7% and 80.5%, respectively. Those in the recipients without hypertriglyceridemia were 95.1% and 86.5%, respectively. The graft survival rate in the recipients with hypertriglyceridemia was lower than that in the recipients without hypertriglyceridemia (p = 0.371). Of 367 recipients, 151 (41.1%) had systolic hypertension 3 years after kidney transplantation. The 5- and 10-year graft survival rates in the recipients with hypertension were 85.6% and 64.7%, respectively. Those of the recipients without hypertension were 95.6% and 83.8%, respectively. The graft survival rate in the recipients with hypertension was lower than that in the recipients without hypertension (p < 0.001). Acute rejection, hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), and hypertension are predictive factors for long-term graft survival. Especially the onset time, number of rejections, and efficacy of treatment for acute rejection would have a significant influence on long-term graft survival.

Entities:  

Mesh:

Year:  2005        PMID: 15654657     DOI: 10.1007/s00268-005-7531-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  The influence of acute rejection on long-term renal allograft survival: a comparison of living and cadaveric donor transplantation.

Authors:  R J Knight; L Burrows; C Bodian
Journal:  Transplantation       Date:  2001-07-15       Impact factor: 4.939

2.  Acute rejection is a risk factor for long-term survival in a single-center analysis of 1544 renal transplants.

Authors:  N Z Galante; H S Tedesco; P G P Machado; A Pacheco-Silva; J O Medina-Pestana
Journal:  Transplant Proc       Date:  2002-03       Impact factor: 1.066

3.  Hyperlipidemia as a risk factor of renal allograft function impairment.

Authors:  M F Carvalho; V Soares
Journal:  Clin Transplant       Date:  2001-02       Impact factor: 2.863

Review 4.  Antihypertensive treatment in renal transplant patients--is there a role for ACE inhibitors?

Authors:  M Hausberg; M Kosch; H Hohage; B Suwelack; M Barenbrock; K Kisters; K H Rahn
Journal:  Ann Transplant       Date:  2001       Impact factor: 1.530

Review 5.  Long-term kidney transplant survival.

Authors:  S Hariharan
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

Review 6.  General health management and long-term care of the renal transplant recipient.

Authors:  D Cohen; C Galbraith
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

7.  Arterial hypertension and renal allograft survival.

Authors:  K C Mange; B Cizman; M Joffe; H I Feldman
Journal:  JAMA       Date:  2000-02-02       Impact factor: 56.272

8.  Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study.

Authors:  G Opelz; T Wujciak; E Ritz
Journal:  Kidney Int       Date:  1998-01       Impact factor: 10.612

9.  Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction?

Authors:  U Frei; R Schindler; D Wieters; U Grouven; R Brunkhorst; K M Koch
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

10.  Clinical profile and course and outcome of late acute rejection episodes in living-related-donor renal allograft recipients.

Authors:  R Mittal; S K Agarwal; S C Dash; S Saxena; S C Tiwari; S N Mehta; U N Bhuyan; N K Mehra
Journal:  Nephron       Date:  1995       Impact factor: 2.847

View more
  5 in total

Review 1.  Ambulatory blood pressure monitoring in pediatric renal transplantation.

Authors:  Tomáš Seeman
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

2.  Clinical Course and Outcomes of Late Kidney Allograft Dysfunction.

Authors:  Viktor Denisov; Vadym Zakharov; Anna Ksenofontova; Eugene Onishchenko; Tatyana Golubova; Sergey Kichatyi; Olga Zakharova
Journal:  J Transplant       Date:  2016-07-10

3.  Identify Survival Predictors of the First Kidney Transplantation: A Retrospective Cohort Study.

Authors:  Ali-Reza Soltanian; Hossein Mahjub; Ali Taghizadeeh-Afshari; Gholamreza Gholami; Hojjat Sayyadi
Journal:  Iran J Public Health       Date:  2015-05       Impact factor: 1.429

4.  Hypertension after renal transplantation.

Authors:  Tomás Seeman
Journal:  Pediatr Nephrol       Date:  2007-10-23       Impact factor: 3.714

Review 5.  Equity or Equality? Which Approach Brings More Satisfaction in a Kidney-Exchange Chain?

Authors:  Arian Hosseinzadeh; Mehdi Najafi; Wisit Cheungpasitporn; Charat Thongprayoon; Mahdi Fathi
Journal:  J Pers Med       Date:  2021-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.